Literature DB >> 7426504

Intrauterine digoxin treatment of fetal paroxysmal tachycardia. Case report.

G Lingman, S Ohrlander, P Ohlin.   

Abstract

A patient with fetal paroxysmal supraventricular tachycardia (PST) with a heart rate above 300 beats/minute in the 29th week of pregnancy is described. The fetus showed signs of severe cardiac failure and was, therefore, digitalized by giving the mother 0.5 mg digoxin intravenously on the first day and the 0.25 mg oral digoxin daily throughout the pregnancy. After one day a normal rhythm was observed. The patient was delivered of a healthy girl after 38 weeks of pregnancy. Digoxin concentrations in samples of umbilical cord vein and artery, intrapartum scalp capillary, and amniotic fluid were almost equal, but somewhat lower than in simultaneously obtained maternal serum. Intrauterine digoxin treatment of fetuses with PST is discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7426504     DOI: 10.1111/j.1471-0528.1980.tb04552.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  5 in total

Review 1.  Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations.

Authors:  A D Mooradian
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

2.  Evaluation of fetal arrhythmias by echocardiography.

Authors:  L D Allan; R H Anderson; I D Sullivan; S Campbell; D W Holt; M Tynan
Journal:  Br Heart J       Date:  1983-09

3.  Arrhythmia and structural abnormalities of the fetal heart.

Authors:  P A Stewart; H M Tonge; J W Wladimiroff
Journal:  Br Heart J       Date:  1983-12

4.  Intrauterine supraventricular tachyarrhythmias and transplacental digitalisation.

Authors:  M Nagashima; T Asai; C Suzuki; M Matsushima; A Ogawa
Journal:  Arch Dis Child       Date:  1986-10       Impact factor: 3.791

Review 5.  Fetal Arrhythmia Diagnosis and Pharmacologic Management.

Authors:  Janette F Strasburger; Gretchen Eckstein; Mary Butler; Patrick Noffke; Annette Wacker-Gussmann
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.